Form D · Biotechnology
Bambusa Therapeutics, Inc.
Boston, MA · CIK 0002044950
Offering snapshot reported Feb 26, 2025 · SEC filing
- Reported sold
- $53.3M Offering amount: $88.9M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 12, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 26, 2025 | Initial | $53,267,941 | No comparison | 16 | SEC filing |
| Jan 8, 2025 | Initial | $5,099,997 | No comparison | 4 | SEC filing |
| Jan 8, 2025 | Initial | $8,999,974 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-539297
Source: Form D, filed Feb 26, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Derek Di Rocco | Director |
| Helmut Jeggle | Director |
| Sean Marett | Director |
| Shanshan Xu | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Marina Park Drive, Suite 1410
Boston, MA, 02210
Boston, MA, 02210